Characterization of Acute HCV Infection and Transmission Networks in People Who Currently Inject Drugs in Catalonia: Usefulness of Dried Blood Spots

Adrián Antuori, Vincent Montoya, David Piñeyro, Lauro Sumoy, Jeffrey Joy, Mel Krajden, Sara González‐Gómez, Cinta Folch, Jordi Casabona, Lurdes Matas, Joan Colom, Verónica Saludes, Elisa Martró, HepCdetect II Study Group – 19 February 2021

Microbiota‐Driven Activation of Intrahepatic B Cells Aggravates NASH Through Innate and Adaptive Signaling

Fanta Barrow, Saad Khan, Gavin Fredrickson, Haiguang Wang, Katrina Dietsche, Preethy Parthiban, Sacha Robert, Thomas Kaiser, Shawn Winer, Adam Herman, Oyedele Adeyi, Marialena Mouzaki, Alexander Khoruts, Kristin A. Hogquist, Christopher Staley, Daniel A. Winer, Xavier S. Revelo – 19 February 2021

Serum Laminin γ2 Monomer as a Diagnostic and Predictive Biomarker for Hepatocellular Carcinoma

Taro Yamashita, Naohiko Koshikawa, Tetsuro Shimakami, Takeshi Terashima, Masatoshi Nakagawa, Kouki Nio, Rika Horii, Noriho Iida, Kazunori Kawaguchi, Kuniaki Arai, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Masao Honda, Azusa Kitao, Satoshi Kobayashi, Shizuko Takahara, Yasuhito Imai, Kenichi Yoshimura, Toshinori Murayama, Yasunari Nakamoto, Eisaku Yoshida, Toru Yoshimura, Motoharu Seiki, Shuichi Kaneko – 19 February 2021

Cardiac Risk Stratification in Liver Transplantation: Results of a Tiered Assessment Protocol Based on Traditional Cardiovascular Risk Factors

Marcus Robertson, William Chung, Dorothy Liu, Rosemary Seagar, Tess O’Halloran, Anoop N. Koshy, Mark Horrigan, Omar Farouque, Paul Gow, Peter Angus – 18 February 2021 – Coronary artery disease (CAD) confers increased perioperative risk in patients undergoing liver transplantation (LT). Although routine screening for CAD is recommended, there are limited data on the effectiveness of screening strategies. We evaluated the safety and efficacy of a 3‐tiered cardiac risk‐assessment protocol that stratifies patients based on age and traditional cardiac risk factors.

LiverLearning®: 2021 Webinar: Use of Serum and Imaging Biomarkers of NAFLD/NASH in Clinical Practice

This on-demand webinar will update the audience on the most recent data in non-invasive testing (NITs) biomarkers in NAFLD/NASH (including use for staging, monitoring disease progression and response to therapy). We will focus on three key areas: serum-based biomarkers, imaging-based biomarkers and how to use combination or sequential NITs. At the conclusion of the webinar, learners will have an update on knowledge of various biomarkers in NAFLD and a path to apply best practices in their setting.Emmanuel A. Tsochatzis Emmanuel A.

Subscribe to